Glen Ridge, NJ, February 20, 2019 – Congenital Hyperinsulinism International (CHI) is thrilled to announce it will be offering a pilot research grant to generate new insights into hyperinsulinism hyperammonemia (HIHA, also called GDH-HI), with the goal of adding to a body of knowledge leading to new and better treatments, and a cure, one day.
“CHI is hoping researchers from all over the world who are passionate about a brighter future for people born with HIHA are inspired to apply for this grant.“
– Randy Hart, HIHA Parent and Board Member, Congenital Hyperinsulinism International
In May, CHI will award the one-year grant. Funding of $70,000 will be available for an innovative,
preclinical, or clinical study that has the potential to lead to: (1) a better HIHA treatment; (2) a cure for
HIHA; or (3) a quality of life improvement for those affected by HIHA.
HIHA is the second most common form of HI. It is caused by a defective GDH (glutamate dehydrogenase) gene. GDH is an enzyme which plays an important role in amino acid metabolism. People with HIHA secrete too much insulin which causes hypoglycemia, especially after a protein rich intake. Those with HIHA also have high ammonia levels in their blood, and often have epilepsy and other neurological issues that are thought to stem from the change in the GDH gene. The only currently available treatment for HIHA helps in the management of hypoglycemia but leaves the high ammonia levels untreated.
A Request for Applications (RFA) will be issued on February 25, 2019. Applications are due on April 8, 2019 by 24:00 EDT. Applications will be reviewed by a committee of experts in the field, and the award will be announced on May 20, 2019. This funding opportunity is open to independent researchers, tenure-track faculty, non-tenure-track faculty or staff, or an equivalent level at a research institution or at a biotechnology/ pharmaceutical company.
CHI is the leading HI patient advocate dedicated to supporting children and adults born with HI. Founded in 2005 by parents of children with HI, the 501(c)3 organization works to support research leading to better treatments and a cure for the rare disease. The nonprofit raises awareness of the dangers of prolonged hypoglycemia and supports families living with the disease. U.S. donations to CHI are tax deductible. This grant was made possible by generous donors to CHI.
CHI Newsletter with the End Of Year HIlights!
We want to share with you how phenomenal 2018 has been for the congenital hyperinsulinism (HI) community and important news. There are so many reasons for hope and optimism. Thank you for your all you do to support the work of CHI, advancing research for better treatments and cures, raising awareness of HI to prevent brain damage and death, and being there for HI families every step of the way. Click here or on the image below to read the newsletter.
Support The Sweetest Cause
Congenital Hyperinsulinism International could not do the work we do without your financial support. Please help us to continue to improve the lives of people living with congenital hyperinsulinism. Your generous donation allows us to continue to raise awareness to increase timely diagnosis, provide educational opportunities, support HI families and help them access the care they need, and support research.
The HI Global Registry Has Launched
Patient-Powered Research for a Brighter Future
Press Release: Glen Ridge, NJ, October 8, 2018 – The HI Global Registry will generate new insights into congenital hyperinsulinism (HI), drive new research for treatments and cures, and support the success of clinical trials.
“The HI Global Registry is a groundbreaking new global online research study powered by patients and their families, developed by CHI with partners around the world.” – Julie Raskin, CHI Executive Director
Congenital Hyperinsulinism International (CHI) is very excited to announce today’s launch of the HI Global Registry. The HI Global Registry provides a convenient online platform for the HI patient community to share their experiences of living with congenital hyperinsulinism (HI). By participating in this study, the patient community will help themselves and researchers better understand HI to advance better treatments, a potential cure, and more timely and accurate diagnoses. (scroll down to read more, or click here for a PDF of this press release. Click on the registry logo below to go directly to the Registry).
The HI Global Registry consists of a series of surveys with questions about health, treatment, development, and quality of life. People with HI or their parents or caregivers can participate from anywhere in the world. Participants will be able to view graphic representations of the responses of the greater HI global community to see how their personal experience fits into the greater whole.
“This is an exciting day. The HI Global Registry is the first global patient registry for those affected by HI. The Registry team has brought together patient representatives from around the world to work with international researchers and clinicians on the development of the Registry and today we are live. This patient-powered project will be a vital resource to better understand HI for years to come.” – Davelyn Eaves Hood, MD, MBA
The HI Global Registry has been developed and hosted on a platform built by the National Organization for Rare Disorders (NORD), the patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them.
HI is a life-threatening genetic disorder that causes severe low blood sugar. In most countries the estimated incidence of HI is approximately 1/25,000 to 1/50,000 births. For those with HI the beta cells of the pancreas secrete too much insulin in an unregulated manner. Excess insulin causes hypoglycemia. Prolonged or severe hypoglycemia can cause seizures, permanent brain damage or death, if left untreated. Due to the dangers of hypoglycemia, HI requires timely diagnosis.
CHI, a 501(c)3, is a lifeline to those born with congenital hyperinsulinism (HI) and their families. CHI is the global organization dedicated to supporting children and adults born with HI. CHI is a leading source of funding for research for better treatments and cures, and the foremost advocate for increased
awareness and better medical protocols for HI to reduce preventable brain damage and death from prolonged hypoglycemia.
For more information about this topic, please visit www.congenitalhi.org/higlobalregistry or call Jacqueline Kraska, CHI Research and HI Global Registry Program Director, at 973-842-7559 or email at firstname.lastname@example.org. You may also contact Davelyn Hood, HI Global Registry Principal Investigator, at email@example.com.
View the Be My Sugar Gallery to learn about hyperinsulinism and the children and families who live with it.
Click the image above to view our Be My Sugar campaign leading up to the 2016 Rare Disease Day!
Watch our video to learn about hyperinsulinism and the children and families who live with it. The video emphasizes the importance of early diagnosis, research, and support for hyperinsulinism families.
New! CHI “What is Congenital Hyperinsulinism” Posters
Available for download and printing on our new CHI Posters page; available in English, Spanish, French, German, Italian, Portuguese, and Catalan.